1. To become familiar with the most common monogenic etiologies of neonatal/congenital diabetes, with emphasis on mutations in the KATP channel that can be treated with sulfonylureas.
2. To appreciate the difference in treatment, disease outcome and quality of life that can result from properly diagnosing patients with monogenic diabetes.
3. To understand the barriers to translating genetic findings into clinical treatment decisions.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation